XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets

Posted by Francis Steltz on Sep 11th, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Investment analysts at Brookline Capital Markets boosted their Q3 2026 EPS estimates for shares of X4 Pharmaceuticals in a research report issued to clients and investors on Tuesday, September 8th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of ($0.20) per share for the quarter, up from their prior forecast of ($0.22). The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.71) per share. Brookline Capital Markets also issued estimates for X4 Pharmaceuticals’ Q4 2026 earnings at ($0.25) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.90) EPS, FY2028 earnings at ($1.29) EPS, FY2029 earnings at ($0.15) EPS and FY2030 earnings at $2.86 EPS.

Other analysts also recently issued reports about the stock. Wells Fargo & Company initiated coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They set an “overweight” rating and a $11.00 price target on the stock. Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th. Finally, Leerink Partners initiated coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 target price on the stock. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

Check Out Our Latest Report on X4 Pharmaceuticals

X4 Pharmaceuticals Price Performance

Shares of NASDAQ XFOR opened at $3.40 on Friday. The stock has a market capitalization of $337.11 million, a price-to-earnings ratio of -2.83 and a beta of 0.39. X4 Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $4.83. The firm’s 50 day simple moving average is $4.03 and its 200-day simple moving average is $4.03. The company has a debt-to-equity ratio of 0.49, a current ratio of 11.30 and a quick ratio of 11.02.

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. The company had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative return on equity of 63.05% and a negative net margin of 568.80%.

Insider Transactions at X4 Pharmaceuticals

In related news, Chairman Adam R. Craig sold 47,436 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $4.44, for a total transaction of $210,615.84. Following the completion of the sale, the chairman directly owned 328,651 shares of the company’s stock, valued at approximately $1,459,210.44. This trade represents a 12.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO David Kirske sold 8,543 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the sale, the chief financial officer owned 167,750 shares in the company, valued at approximately $714,615. This trade represents a 4.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 80,555 shares of company stock worth $356,126 in the last ninety days. Insiders own 1.13% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Pettinga Financial Advisors LLC acquired a new stake in X4 Pharmaceuticals in the 2nd quarter valued at approximately $47,000. SummitTX Capital L.P. purchased a new position in X4 Pharmaceuticals in the 1st quarter valued at approximately $46,000. Squarepoint Ops LLC purchased a new position in X4 Pharmaceuticals in the fourth quarter valued at $50,000. Two Sigma Investments LP purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter valued at about $47,000. Finally, WINTON GROUP Ltd grew its holdings in X4 Pharmaceuticals by 35.8% during the 2nd quarter. WINTON GROUP Ltd now owns 14,400 shares of the company’s stock worth $67,000 after acquiring an additional 3,800 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

(Get Free Report)

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.